Adverts

Open Access Articles- Top Results for Arformoterol

Arformoterol

</th></tr></th></tr>
Arformoterol
File:Arformoterol.svg
Systematic (IUPAC) name
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a602023
Licence data US FDA:link
  • US: C (Risk not ruled out)
nebuliser
Pharmacokinetic data
Protein binding 52–65%
Half-life 26 hours
Identifiers
67346-49-0 7pxY
None
PubChem CID 3083544
DrugBank DB01274 7pxY
ChemSpider 2340731 7pxY
UNII F91H02EBWT 7pxY
ChEBI CHEBI:408174 7pxY
ChEMBL CHEMBL1201137 7pxN
Chemical data
Formula C19H24N2O4
344.405 g/mol
 14pxN (what is this?)  (verify)

Arformoterol is a long acting beta-adrenoceptor agonist drug indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

  1. ^ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14. 

External links


Lua error in package.lua at line 80: module 'Module:Buffer' not found.